New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
16:15 EDTTHC, HUMHumana, Tenet sign new multi-year national agreement
Tenet Healthcare (THC) and Humana (HUM) have signed a new multi-year contract extension that provides Humana members with traditional commercial plans continued in-network access to Tenet’s 79 hospitals, 193 outpatient centers and more than 1,800 employed physicians. In addition, for the first time, patients enrolled in Humana’s healthcare Exchange plans in Atlanta, Birmingham, Houston, Memphis and San Antonio will have access to Tenet hospitals, related facilities and employed and affiliated physicians. Humana Exchange members in Chicago, Detroit and Phoenix continue to have access. Humana also has an existing agreement with Tenet that provides its Medicare Advantage members with in-network access to Tenet facilities.
News For HUM;THC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
08:49 EDTHUMHumana price target raised to $193 from $167 at Oppenheimer
Oppenheimer increased its price target on Humana (HUM) to reflect the company's sale of Concentra to Select Medical (SEM) and Welsh Carson for $1.055B. The firm says that the deal is likely to be supportive of Humana's earnings growth over the longer term. It keeps an Outperform rating on the shares.
07:43 EDTHUMDaVita subpoenas have mixed outcomes, says William Blair
Subscribe for More Information
07:41 EDTHUMHumana received DOJ request for information on Medicare
Subscribe for More Information
March 23, 2015
16:20 EDTTHCOn The Fly: Closing Wrap
Stocks on Wall Street opened in relatively quiet fashion and remained that way throughout the session until a sharp selloff in the closing minutes. For most of the day the averages moved in a narrow range, as the Dow broke its streak of consecutive days with triple digit moves. Like stocks, the oil markets had a quiet session that stood out amid the recent volatility in crude prices. A late day drop prevented the major stock indexes from adding to the big gains they'd notched on Friday. ECONOMIC EVENTS: In the U.S., the Chicago Fed's national activity index fell to -0.11 in February, below expectations for a reading of 0.10. Existing home sales rose 1.2% to a 4.88M rate in February, which was below the consensus forecast for them to grow 2% to a 4.92M unit rate. COMPANY NEWS: Shares of Kansas City Southern (KSU) declined $9.21, or 7.96%, to $106.48 after the railroad operator lowered its fiscal year revenue guidance to reflect slower year-to-date carload growth primarily from the energy sector, along with a continued deterioration in the value of the Mexican peso against the U.S. dollar and lower fuel surcharge revenues driven by lower WTI prices. The revenue warning appeared to weigh on others in the rail industry as well, with Union Pacific (UNP) falling $4.67, or 3.98%, to $112.78, Norfolk Southern (NSC) dropping $3.87, or 3.5%, to $106.56 and Canadian National (CNI) sliding $1.13, or 1.65%, to $67.24. MAJOR MOVERS: Among the notable gainers was ImmunoGen (IMGN), which gained $1.25, or 16.8%, to $8.69 after Takeda (TKPYY) licensed rights to use the company's antibody drug conjugate technology. Also higher was Tenet Healthcare (THC), which rose $2.45, or 4.94%, to $52.07 after agreeing to combine its short-stay surgery and imaging center assets into a new joint venture with United Surgical Partners International. Tenet will initially own 50.1% of the joint venture and will consolidate its financial results and will have a path to full ownership of USPI over the next five years through a put/call structure, the company noted. Among the noteworthy losers was MEI Pharma (MEIP), which plunged $4.37, or 69.37%, to $1.93 and was downgraded by at least four Wall Street research firms after the combination of Pracinostat and azacitidine showed no difference in the rate of complete remission, the primary endpoint of a Phase II study, compared to azacitidine alone. Also lower were shares of Vertex (VRTX), which fell $5.21, or 3.98%, to $125.79 after reporting data from a study evaluating VX-661 in combination with ivacaftor in cystic fibrosis that JPMorgan said was generally below expectations. INDEXES: The Dow fell 11.61, or 0.06%, to 18,116.04, the Nasdaq lost 15.44, or 0.31%, to 5,010.97, and the S&P 500 dropped 3.68, or 0.17%, to 2,104.42.
16:02 EDTTHCTenet announces partnership with Baylor Scott & White Health
Subscribe for More Information
12:17 EDTHUMOn The Fly: Midday Wrap
Subscribe for More Information
10:05 EDTTHCTenet added to short-term buy list at Deutsche Bank
09:07 EDTHUMSelect Medical agrees to acquire Concentra through JV with Welsh Carson
Subscribe for More Information
09:04 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
Humana (HUM) has reached a definitive agreement to sell the stock of its wholly-owned subsidiary, Concentra, to MJ Acquisition Corporation, a joint venture between Select Medical Holdings Corporation (SEM), an operator of specialty hospitals and outpatient rehabilitation clinics in the U.S., and Welsh, Carson, Anderson & Stowe XII, L.P., a private equity fund, for approximately $1.055B in cash, subject to customary adjustments. Humana acquired Concentra in December 2010. Subsequently, the assets of certain privately-operated Community Based Outpatient Clinics were transferred into Concentra. Additionally, Humana has divested certain Concentra non-core assets over the past four years. The decision to divest Concentra demonstrates the company’s commitment to its previously announced business portfolio review. Humana will continue performing its review of the alignment and return potential of businesses across the organization to ensure each supports the company’s integrated care delivery strategy and earns the appropriate return on invested capital. The Concentra transaction is anticipated to close during the second quarter of 2015 subject to Hart Scott Rodino regulatory clearance and customary closing conditions. Humana anticipates using the net proceeds from the transaction to advance its strategic growth priorities, to fund additional share repurchases under its existing $2 billion authorization and for general corporate purposes. Goldman, Sachs & Co. is acting as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP is acting as legal advisor to Humana. Concentra reported revenues for the year ended December 31, 2014 were approximately $1B. Humana anticipates the Concentra divestiture will be slightly dilutive to 2015 EPS excluding any one-time gain expected upon the close of the transaction.
09:02 EDTHUMHumana reiterates FY15 EPS view $8.50-$9.00, concensus $8.87
Subscribe for More Information
09:02 EDTHUMHumana to sell Concentra to Select Medical, Welsh Carson for $1.055B in cash
08:07 EDTTHCBofA/Merrill healthcare high yield analyst has analyst/industry conference call
Healthcare High Yield Analyst Bland provides an update on the current state of the bond markets and the ability of healthcare providers to utilize debt financing on an Analyst/Industry conference call to be held on March 24 at 10 am.
06:04 EDTTHCTenet, United Surgical Partners and Welsh Carson announce new joint venture
Subscribe for More Information
March 22, 2015
20:45 EDTTHCTenet getting close to deal for United Surgical Partners, WSJ says
Subscribe for More Information
March 20, 2015
08:18 EDTTHC, HUMLeerink healthcare services analyst holds an analyst/industry conference call
Healthcare Services Analyst Gupte discusses Sustainable Growth Rate (SGR) and the proposed pay-fors and implications For Healthcare Services on an Analyst/Industry conference call to be held on March 20 at 11 am.
March 16, 2015
09:04 EDTHUMHumana announcse completion of $500M accelerated share repurchase program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use